Phase 2 Confirmatory Study of Cemiplimab (350 Mg IV Q3W) in Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Study 1540 Group 6. J of Skin 2023, 7 (2), s175. https://doi.org/10.25251/skin.7.supp.175.